Aiolos Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aiolos Bio, Inc. - overview
Established
2023
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2023 by co-founders Khurem Farooq and Tony Adamis, Aiolos Bio, Inc. offers a wide range of products catering to various immune conditions, such as asthma, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). In October 2023, Aiolos Bio, Inc. raised USD 245 million in Series A funding co-led by investors Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with participation from another investor, RA Capital Management.
In January 2024, GlaxoSmithKline Plc agreed to acquire Aiolos Bio, Inc. for USD 1 billion. The company offers an anti-TSLP (thymic stromal lymphopoietin) asset, AIO-001, a monoclonal antibody specifically designed to target and block TSLP, a known driver of inflammation in conditions like asthma. This approach represents a paradigm shift in the management of asthma, providing patients with a significantly reduced treatment burden, thereby allowing them to lead fuller lives.
The company plans to use the October 2023 funding to support the advancement of its Phase 2-Ready TSLP antibody.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.aiolosbio.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Aiolos Bio, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.